|
|
 |
|
Viewing report
|
|
|
|
Key Pharma Industry Trends 2012
Pharma-Reports, Jan 2012, Pages: 80
The global pharmaceutical industry has enjoyed steady growth in recent years, despite a global economic downturn. But with patent expiries, stricter regulations, and U.S. healthcare reforms, the pharmaceutical industry is increasingly under pressure to maintain its steady revenue flow.
With the patent cliff looming through 2014, many pharmaceutical companies are restructuring to reestablish their industry dominance. They are reinventing themselves through mergers and acquisitions, or are signing licensing deals in order to survive.
Real Publishing presents a study of key pharma industry trends. This report offers an analysis of the impact of those trends, and reforms and regulations, particularly in the U.S. and the EU.
Key Trends Explored:
- Generic drug manufacturers are gearing up to take advantage of the opportunities presented by the many patent expiries
- What trends are impacting the leading generic drug manufacturers such as Teva, Sandoz, and others
- What government regulations and policies will effect pharma company bottomlines in 2012 and beyond?
- How are pharma companies using mergers and acquisitions to maintain a competitive edge?
- What is the state of the current global pharmaceutical industry and where is it growing?
- Pharmerging countries contribute approximately half of growth, with China as third-largest market
Global Pharma Industry Trends Examined:
- Challenge of Patent Expiries
- Challenges Facing the Generic Market
- Cost-savings with Generics
- Enforcing Prescription by INN
- Providing Incentives for Pharmacists
- Innovation in Existing Reference Pricing Systems
- Relation between U.S. Healthcare Reform and Generic Uptake
- Change Likely for U.S. Generics' Market Entry
- Pharmaceuticals and Biologics
- Tough Regulations in the EU
- Innovation by Generic Producers
- Impact of Price Cuts by Governments
- Preference of Brand Loyalty
- U.S. Healthcare Reforms Tough on Generic Companies
- Emergence of Pay-for-Delay Model
Pharma Trends in BRIC Countries Examined:
- Impact of Population Boom
- Favorable Exclusivity Requirements for Generics
- Challenges to Patent Extensions for Branded Drugs
- Role of Compulsory Licensing
- Preference for Branded Generics
- Strict Price Regulations and Strong Industry Competition
- Limited Market Access for Foreign Players
- Requirement of Improvement in Good Manufacturing Practices
Industry Players Mentioned:
- Teva, the Generic Market Leader
- Sandoz Acquisition Spree
- Mylan Targeting Immature Markets
- Sanofi Set to Become Market Leader
This report is a must-read for pharma industry executives, researchers, consultants, and investors.
|
|
|
|
